Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on December 9, 2004. The filing reports material corporate governance changes effective as of the report date, specifically regarding the departure and appointment of principal financial officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Departure: Steven M. Plumb was removed from his position as Chief Financial Officer (CFO) effective December 9, 2004.
- Appointment: Carrie E. Carlander was appointed as Chief Financial Officer, Vice President of Finance, and Treasurer effective December 9, 2004.
- Additional Appointment: A press release referenced in the filing notes the appointment of Brian M. Culley as Vice President of Business Development.
Management Commentary and Risks
The filing details the professional background of the new CFO, Carrie E. Carlander, noting her previous roles at Singlefin, Inc., SofLinx, Inc., V-Enable, Inc., and Websense Inc. The document states that Ms. Carlander has no family relationships with other directors or officers and has not entered into any transactions with the company. No specific risks, contingencies, or unusual items regarding financial operations are disclosed in this text.
Investor Verification Checklist
- Verify the correct registrant name is AdventRX Pharmaceuticals, Inc., as the input metadata referenced Savara Inc.
- Confirm the effective date of the CFO transition (December 9, 2004) against internal records.
- Review the referenced press release (Exhibit 99.1) for details on the appointment of Brian M. Culley.
- Check subsequent filings for the first financial report prepared under the new CFO's tenure.